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Open access under CC BYTwo closely related binding modes have previously been proposed for the ATP-competitive benzimid-
azole class of checkpoint kinase 2 (CHK2) inhibitors; however, neither binding mode is entirely consistent
with the reported SAR. Unconstrained rigid docking of benzimidazole ligands into representative CHK2
protein crystal structures reveals an alternative binding mode involving a water-mediated interaction
with the hinge region; docking which incorporates protein side chain ﬂexibility for selected residues
in the ATP binding site resulted in a reﬁnement of the water-mediated hinge binding mode that is con-
sistent with observed SAR. The ﬂexible docking results are in good agreement with the crystal structures
of four exemplar benzimidazole ligands bound to CHK2 which unambiguously conﬁrmed the binding
mode of these inhibitors, including the water-mediated interaction with the hinge region, and which
is signiﬁcantly different from binding modes previously postulated in the literature.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction As part of our in-house drug discovery project, we were partic-Checkpoint kinase 2 (CHK2) is a serine/threonine protein kinase
and a component of the ATM-mediated response to double-strand
DNA breaks. It has been postulated that selective inhibition of
CHK2 could increase the efﬁcacy of genotoxic cancer therapies in
a p53 mutant background by modulating resistance pathways
and may also be radioprotective to normal p53 wild-type tissues.1,2
Recent results demonstrate that selective inhibition of CHK2 in
combination with PARP inhibition could also be therapeutically
beneﬁcial in cancer therapy.3 Small molecule inhibitors of CHK2
have been disclosed including the staurosporine analogue UCN-
01,4,5 an indoloazepine derivative of hymenialdisine,6 isothiazole
carboxamidines,7,8 bisguanylhydrazones,9,10 the dual CHK1/CHK2
inhibitor AZD776211 as well as 3,5-diaryl-2-aminopyridines12 and
2-(quinazolin-2-yl)phenols, of which the potent and selective
chemical tool CCT241553 is an example.13,14ATM, ataxia telangiectasia
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 license.ularly intrigued by a published series of benzimidazole CHK2
inhibitors for which two closely related binding modes have been
proposed, neither of which appeared entirely consistent with the
reported SAR (vide infra).15–17 Benzimidazole is a common kinase
inhibitor scaffold with compounds reported to inhibit NEK2,18
IKKe,19 GSK3b,20 and p3821 as well as CHK2.15–17 Analysis of the
52 protein kinase crystal structures in the protein databank
(PDB)22,23 which incorporate a benzimidazole-containing ligand
revealed multiple binding modes. In some of these the benzimid-
azole is acting as part, or all, of the hinge-binding motif18–21
whereas others indicate a scaffolding role without evidence for di-
rect hinge binding.24–26 However, this set of protein–ligand struc-
tures does not contain any benzimidazole-based ligands bound to
CHK2. The two closely related binding modes that have been pro-
posed for the published class of benzimidazole CHK2 inhibitors
both postulate that a pendant carboxamido substituent on the
benzimidazole scaffold interacts directly with the hinge
(Fig. 1).15,16 In one proposed binding mode, the carboxamide group
forms two canonical hydrogen bonds with Glu302 and Met304
(Fig. 1A), whilst in the other, the carboxamide interacts exclusively
with Met304 (Fig. 1B).16
Literature SAR includes analogues where the benzimidazole
scaffold has been modiﬁed or replaced (Table 1) and has been pro-
posed to be consistent with binding mode B.15,16 For example, the
loss of afﬁnity observed upon replacement of the 5-carboxamido
group (compound 1, Table 1) with a carboxylic acid, nitrile or nitro
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Figure 1. Two postulated binding modes of benzimidazole CHK2 inhibitors: (A) interaction with Glu302 and Met304 of the hinge; (B) interaction with Met304 of the hinge.
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Table 1) has been postulated to be consistent with binding of the
5-carboxamido group directly to the hinge. Preference for binding
mode B was proposed based upon the potency of the primary sul-
phonamide (compound 7, Table 1) in which interaction with the
hinge through a bidentate H-bond donor–acceptor interaction to
Met304 was proposed to place the polar sulphonamide in a more
favourable hydrophilic environment.15 However, a substructure
search of the sulphonamide motif in the PDB22,23 revealed no
examples of ligands with a sulphonamide bound to the hinge re-
gion of a kinase. Moreover, signiﬁcant loss of potency was observed
upon methylation of either benzimidazole nitrogen (compounds 8
and 9, Table 1) and upon replacement of the benzimidazole with
the benzisoxazole or pyrazolopyrimidine scaffold (compounds
10, 11 and 12, Table 1).16 In summary, existing biochemical SAR
is consistent with an essential role for all four polar atoms of the
benzimidazole carboxamide scaffold in its binding to CHK2 and
we postulated that alternative binding modes may better explain
this SAR. We therefore set out to explore alternative CHK2 binding
modes for the benzimidazole class by application of unconstrained
rigid docking, ﬂexible side chain docking and protein–ligand
crystallography.
In silico docking of small molecules into protein binding sites
has become a powerful tool for medicinal chemistry design27,28;
however, many docking protocols treat the protein as a rigid en-
tity and, given the inconsistencies between reported SAR and the
proposed benzimidazole binding modes in CHK2, we explored
whether the introduction of side chain ﬂexibility into the dock-
ing protocol would produce binding modes more consistent with
the experimental SAR. A number of methods have been devel-
oped to introduce protein ﬂexibility into docking protocols.29–32
One approach is to interrogate multiple crystal structures of
the same protein;33,34 however, relatively few cases exist for
which multiple crystal structures representing different protein
conformations are available. Alternatively, computational meth-
ods can be applied to simulate protein conformational ﬂexibility
(e.g. by molecular dynamics);35–38 however, such methods are
computationally intensive and artefact binding site conforma-
tions may be invoked. An alternative, and computationally less
intensive approach, is to introduce protein side chain ﬂexibility
during the ligand docking process. A number of such methods
have been developed39 and can be grouped into ‘knowledge-
based’ and ‘induced-ﬁt’ approaches.40,41 Knowledge-based ap-
proaches sample known side chain conformations from multiple
crystal structures of a particular protein, which again requires
their availability. Induced-ﬁt approaches allow selected side
chains in a single protein structure to move within a predeﬁned
range to sample a continuum of side chain conformations during
ligand docking. We applied best practice unconstrained rigid
docking and an induced-ﬁt ﬂexible docking protocol to establish
the preferred binding mode of the benzimidazole inhibitor class
in CHK2 and compared this predicted binding mode with the
crystal structures of four exemplar benzimidazole inhibitors
bound to CHK2.2. Results and discussion
2.1. Analysis of literature CHK2 protein–ligand crystal
structures
We divided the 19 publicly available CHK2 protein–ligand
crystal structures into two groups. The ﬁrst comprises crystal
structures in which the ligand mimics ADP and interacts with
the hinge region of CHK2 through one or two hydrogen bonds
between the ligand and residues Glu302 and Met304
(Fig. 2A).42 The second comprises 9 crystal structures with li-
gands such as NSC109555 (Fig. 2B)43 and closely related deriv-
atives, for example PV1019,10 in which interaction with the
hinge is mediated through a bound water molecule. The rmsd
of this conserved water molecule between the 9 crystal struc-
tures is 0.62 Å. The binding mode of ADP corresponds to one
of the closely related hinge binding modes postulated for the
benzimidazole series (Fig. 1A).16 Intriguingly, the postulated
benzimidazole binding mode, which involves a bidentate hydro-
gen bond donor and acceptor interaction only to Met304
(Fig. 1B), is not represented in the currently available CHK2
protein–ligand crystal structures.
2.2. Rigid docking of benzimidazole inhibitors
We carried out best practice unconstrained rigid docking using
a selected set of 50 potent compounds from the published benz-
imidazole series (Table S1).15–17 We chose the structures of CHK2
bound to ADP (PDB ID: 2CN5) and to NSC1095555 (PDB ID:
2W0J) as representative high resolution parent structures for dock-
ing [2.25 and 2.05 Å, respectively]. To validate the suitability of
these structures for docking, ligands were removed and re-docked
into the empty structures using GOLD.44 In the NSC109555-bound
structure the water molecule mediating interaction of the inhibitor
with the hinge was retained. In both cases the ligand poses with
the best scores had the same binding mode and interactions as ob-
served in the respective crystal structures.
We subsequently docked the selected set of 50 active benzimid-
azole inhibitors (Table S1) and an inactive control set of inhibitors
(compounds 8–12, Table 1) into the two CHK2 structures using the
interaction with the hinge residues (Glu302 and Met304) as a key
requirement for a good solution. None of the inactive control set of
inhibitors bound in either protein conformation. In the structure
representing the ADP-bound CHK2 conformation (PDB ID: 2CN5),
hydrogen bond interactions with both Glu302 and Met304 were
observed for the lowest energy poses of 14 active compounds
(compounds: 1, 13, 15, 16, 18, 19, 20, 22, 30, 33, 38, 39, 47 and
59); the other 36 compounds did not make these interactions.
However, even for the 14 ligands that did bind to the hinge, no
additional hydrogen bonds with the protein were identiﬁed from
the Protein–Ligand Interaction Fingerprint (PLIF, Fig. 3). By con-
trast, 39 of the 50 compounds were found to bind via the mediat-
ing water molecule using the CHK2 conformation derived from the
NSC109555-bound crystal structure. However, additional polar
Table 1
Structure activity relationships for the benzimidazole series of CHK2 inhibitors
No. Structure CHK2 IC50 (nM)
1
N
H
NH2N
O
O 55 ± 31
15
2
N
H
NHO
O
O 640 ± 210
15
3
N
H
N
N
O 1900 ± 610
15
4 1500 ± 720 15
5 1400 ± 550 15
6
N
H
NN
O
O >10000
15
7 290 ± 90 15
8 >10000 16
9 1540 16
10
O
NH2N
O
O
>10000 16
11
N
OH2N
O
O
>10000 16
12 >10000 16
Numbering to denote the regiochemistry of benzimidazole methylation is shown
for compounds 8 and 9.
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PLIF, were suboptimal for all 39 compounds (Fig. 3).
In summary, an unconstrained rigid docking protocol yielded
a higher hit rate when applied to the NSC109555-derivedprotein structure 2W0J versus the ADP-derived protein structure
2CN5; however, neither protein structure provides binding
mode solutions consistent with the importance of interactions
from all 4 polar atoms of the benzimidazole–carboxamide scaf-
fold, as demonstrated by the experimental SAR (vide supra and
Table 1).
2.3. Flexible docking of benzimidazole inhibitors
We hypothesised that rigid docking may preclude the optimal
orientation of protein side chains in the ATP binding site and ap-
plied a docking protocol incorporating side chain ﬂexibility to
both binding modes of CHK2 exempliﬁed by protein structures
2W0J and 2CN5. Flexibility of up to 10 protein side chains can
be explored using the commercial program GOLD.44,45 Limiting
the number of residue side chains treated as ﬂexible minimises
the generation of false positive results whilst allowing a signiﬁ-
cant number of protein conformations to be generated. However,
care has to be taken to ensure an objective choice of residues
treated as ﬂexible. In brief, we ﬁrst applied a distance cut-off,
based upon our rigid docking results for protein structures
2CN5 and 2W0J, to include all protein residues of the respective
ligand-binding site with the potential to be treated as ﬂexible.
This criterion recognises that signiﬁcant protein conformational
change and associated energetic penalties are incurred for reposi-
tioning side chains distant from the ligand. Secondly, proximal
glycine and alanine residues were deselected because they have
no ﬂexible side chain. Thirdly, we reasoned that, during the dock-
ing process, only residue side chains would be treated as ﬂexible
and interactions with the protein backbone would be unlikely to
inﬂuence the outcome. Therefore, proximal residues interacting
only through their backbone atoms were not selected for side
chain ﬂexibility. Fourthly, residues which have their side chain
pointing away from the ligand were deselected, again recognising
that signiﬁcant protein conformational changes and associated
energetic penalties are incurred for repositioning of side chains
distant from the ligand. Application of these criteria reduced
the number of selected residues to 16 and 27 in the 2CN5 and
2W0J structures, respectively (Table S2, Supplementary data).
Deﬁning objective criteria for residue selection in ﬂexible docking
protocols has been reported to be difﬁcult,31,32 and consistent
with this literature precedent, the remaining residues were man-
ually inspected and residues with side chain ﬂexibility impaired
by hydrogen bonds and/or hydrophobic interactions with neigh-
bouring residues were deselected. Finally, residues deeply buried
in the binding pocket were prioritised over those on the protein
surface until the limit of 10 was obtained. After application of
these criteria, Cys231, Val234, Lys249, Glu308, Asp347, Glu351,
Asn352, Asp368, Leu354 and His371 in the ADP-bound structure
2CN5; and Leu226, Val234, Lys249, Leu301, Glu308, Asp311,
Leu354, Gln358, Thr367 and Asp368 in the NSC109555-bound
structure 2W0J were assigned to be ﬂexible during the docking
runs.
The set of 50 biochemically active benzimidazole inhibitors
was docked into the two parent CHK2 structures allowing side
chains of the ten selected residues in each structure to ﬂex. For
the ADP-derived CHK2 conformation, 40 compounds were pre-
dicted to bind to the hinge region via hydrogen bonds between
the benzimidazole–carboxamide and both Glu302 and Met304.
Of these compounds, 18 were predicted to form one or more
additional hydrogen bonds to the protein (Table S3, Supplemen-
tary data). For the NSC109555-derived CHK2 conformation, 27
compounds were predicted to interact with the hinge via the
mediating water molecule; of these, 24 compounds were pre-
dicted to form one or more additional hydrogen bonds with the
protein (Table S4, Supplementary data).
Figure 3. Number of polar interactions formed by: (A) Ligands which docked via the hinge to the apo-structure derived from the ADP-bound structure (PDB ID: 2CN5) (B).
Ligands which docked via the mediating water molecule to the apo-structure derived from the NSC-109555-bound structure (PDB ID: 2W0J).
Figure 2. Binding of (A) ADP to CHK2 (PDB ID: 2CN5)42 and (B) NSC109555 to CHK2 (PDB ID: 2W0J).43 Hydrogen bonds between the ligand and the hinge region are indicated
with black dashed lines.
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To objectively prioritise the multiple resultant ligand-induced
protein conformations, we docked the dataset of 50 biochemically
active ligands (Table S1, Supplementary data) into each ligand-
induced protein conformation using an unconstrained rigid
docking protocol. We reasoned ﬁrstly, that use of a ligand-induced
protein conformation in a subsequent rigid docking protocol
should deliver a similar binding mode for compounds similar to
the docked ligand; and secondly that the binding mode of a ligand
obtained using ﬂexible docking should be reproduced by rigid
docking into the protein conformation induced by that ligand.
We then analysed the trade-off between the number of polar
interactions formed in a ligand-induced binding mode and the
number of docked ligands adopting that particular binding
mode (Fig. 4 and Supplementary Tables S3 and S4). We recognise
that polar interactions are only one component of the total
protein–ligand interaction energy; however, optimisation of such
interactions, and minimisation of unsatisﬁed ligand H-bond
valencies which incur desolvation penalties, are also signiﬁcant
drivers of ligand efﬁcient binding and, in this case, is consistent
with the observed SAR. We selected optimal solutions closest to
the trade-off surface and where multiple solutions lay close to
the surface, preference was given to those with the highest number
of polar atoms involved in hydrogen bonding.
For the ADP-derived CHK2 protein conformation, the protein
conformation induced by ligand 13 has the optimal balance of ahigh number of docked ligands (30 out of a possible 50) that form
a high number of hydrogen bonds (3 out of a possible 4) (Fig. 4A).
The three polar interactions observed in the ligand 13-induced
conformation are the two hydrogen bonds to the hinge (Glu302
and Met304) and an interaction between the carboxylate side
chain of Asp368 and the N3 atom of the benzimidazole scaffold
(Fig. 5A). For the NSC109555-derived CHK2 protein conformation,
the protein conformation induced by ligand 30 has the optimal bal-
ance of a high number of docked ligands (25 out of a possible 50)
that form the highest possible number of hydrogen bonds (4 out of
a possible 4) (Fig. 4B). The ligand 30-induced conformation reveals
hydrogen bonds between the conserved water molecule to nitro-
gen N1 as well as residue Glu308 to nitrogen N3 of the benzimid-
azole scaffold and interactions from the primary carboxamide
moiety to side chains Thr367 and Asp368 which are adjacent to
the catalytic lysine residue Lys249 (Fig. 5B). Docking of the nega-
tive control set (8 to 12, Table 1) into the ligand 13- or ligand
30-induced structures showed that none of these ligands achieved
four hydrogen bonds to the scaffold in either induced structure.
Considering all possible solutions, these results indicate that the
ligand 30-induced conformation provides the optimal compromise
of a high number of hydrogen bonds (4 out of a possible 4) adopted
by a high number of biochemically active ligands (50%) docked into
this ligand-induced protein conformation. Thus, the introduction
of side chain ﬂexibility into the docking protocol delivers an opti-
mal binding mode mediated by a conserved water molecule to the
hinge region. This binding mode is consistent with the observed
Figure 5. Ligand 13-induced protein conformation (A) in which the benzimidazole carboxamide forms hydrogen bonds with Glu302 and Met304 and ligand 30-induced
protein conformation (B) in which a hydrogen bond is formed to the water molecule. Hydrogen bonds are depicted as dashed black lines.
Figure 6. Overlay of the ﬂexible residues in the binding sites of the NSC109555-bound crystal structure (green, PDB ID: 2W0J) and ligand 30-induced protein structure
(purple). Shown is (A), the CHK2 binding site highlighting residues which adopt a different conformation in the ligand 30-induced protein structure (purple) and (B), a cut
away depiction highlighting residues which adopt a different conformation in the ligand 30-induced protein structure (purple) versus the parent crystal structure (green, PDB
ID: 2W0J); arrows indicate side chains that have changed conformation signiﬁcantly. The ligand pose is taken from the ligand 30-induced conformation.
Figure 4. Trade-off surface for selecting the optimal ligand-induced ADP-derived protein conformation (A) and the optimal ligand-induced NSC109555-derived protein
conformation (B). Each red dot denotes a different ligand-induced protein structure and numbers in bold within the dot denote the ligand used to generate the ligand-induced
structure. For each plot, the x-axis denotes the number of polar atoms of the scaffold involved in hydrogen bonding in the respective ligand-induced structure; the y-axis
denotes the number of docked ligands in the respective ligand-induced structure which show 0–4 polar interactions.
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two closely related binding modes previously postulated in the lit-
erature.15–17
We compared the optimal ligand 30-induced conformation
with the crystal structure 2W0J (Fig. 6). Of the 10 residues treated
as ﬂexible, all hydrophobic protein side chains are aligned similarly
in both the ligand 30-induced conformation and in 2W0J. However,
polar residues Lys249, Asp311 and Glu308 differ in their side chain
conformation and, particularly in the case of Glu308, facilitate the
formation of optimal hydrogen bonding interactions in the ligand-
induced structure (Fig. 6). Taken together, these results demon-
strate that ﬂexible side chain docking reveals polar side chain
interactions important to the ligand binding mode and consistent
with the observed SAR. Should ﬂexible polar side chains change
conformation most signiﬁcantly in ligand-induced models, then
selection of residues for ﬂexible docking could be restricted to
proximal polar residues.
2.5. CHK2 protein–ligand crystallography
To validate the output from ligand-induced ﬂexible docking, we
solved the crystal structures of CHK2 co-crystallised with com-
pounds 19, 30, 44 and 47. In all four protein–ligand structures,
electron density for the benzimidazole scaffold is well deﬁned
and unambiguously shows that the observed binding mode
(Fig. 7) is similar to that reported for NSC109555 (Fig. 2). All four
inhibitors bind with the benzimidazole core sandwiched between
Leu354 at the bottom and Val234 (located in the P-loop) in the
ceiling of the ATP pocket. The phenyl ring on the benzimidazole
2-position is positioned between the loop extending from the
hinge region and Leu226 of the P-loop. The amide moiety interacts
via its oxygen atom with the side chains of Thr367 and Lys249. The
main differences between ligands are observed in their solvent ex-
posed regions. In ligand 30, the chlorophenyl group loosely bindsFigure 7. Crystal structures of CHK2 kinase in complex with inhibitors: (A) compound 30
ribbon format, including cylinder representation for residues within 4 Å of the inhibitor
Fo-Fc density is shown in green and contoured at 3.0r. While strong electron densi
carboxamide scaffold, the weak density for the phenolic substituent of compound 19
chlorobenzyl groups of compound 44 and 47 (Panels C and D) were completely disordered
bridging the benzimidazole and the hinge region was observed in all four structures, but,
H-bonds are indicated by black dotted lines. A summary of the data collection and reﬁnin a hydrophobic pocket at the entrance of the active site deﬁned
by the side chains of Leu226, Leu236, Lys245, Leu303, Glu305
(Fig. 7A). The corresponding phenol in compound 19 is mainly dis-
ordered, but weak density suggests two main conformations
(Fig. 7B). In the two most elaborated compounds, 44 and 47, the
respective benzyl and chlorobenzyl groups are completely disor-
dered; consequently, these groups were not included in the ﬁnal
coordinate ﬁles (Fig. 7C and 7D). Minor differences in the interac-
tions of the four ligands with CHK2 may be due to differences in
data quality and include the presence of the hydrogen bond be-
tween the carboxamide NH2 and Asn352 in compound 19, the ab-
sence of the hydrogen bond between the carboxamide NH2 and the
side chain of Asp368 in compound 30 and 47, and the absence of
the hydrogen bond between the benzimidazole N3 atom and
Glu308 in compound 19. In crystal structures with compounds
30, 44 and 47, the water molecule interacting with the benzimid-
azole N1 atom and the hinge is present, as observed for
NSC109555. Despite a small peak in the Fo-Fc electron density
map corresponding to this water molecule for compound 19, sub-
sequent reﬁnement led to a high B-factor and poor 2Fo-Fc density,
so this water molecule was omitted from the ﬁnal model. This may
be attributable to the slightly lower resolution of this structure;
however, electron density is well deﬁned for both the ligand and
protein hinge region.
The binding mode for compound 30 predicted from ﬂexible
docking is in excellent agreement with the experimentally deter-
mined crystal structures for compounds 19, 30, 44 and 47 bound
to CHK2 (Fig. 8A); the rmsd values for the conserved 2-(4-oxyphe-
nyl)-1H-benzo[d]imidazole-5-carboxamide scaffold between the
predicted binding mode for compound 30 and each of the four
experimentally determined structures range from 0.41 to 0.67 Å.
One difference is the orientation of the 4-chlorophenyl group of
30 (Fig. 8B); however, the two conformations of the 4-chloro-
phenyl observed in the X-ray of 19 suggests that both modes are, (B) compound 19, (C) compound 44 and (D) compound 47. The protein is shown in
(or the water molecule bridging the inhibitor and the hinge). An omit map showing
ty was present in each dataset for the 2-(4-oxyphenyl)-1H-benzo[d]imidazole-5-
(Panel B) suggested two alternate conformations for this moiety. The benzyl and
, and have not been modelled. Electron density corresponding to the water molecule
after reﬁnement, was omitted from the model for compound 19 (Panel B). Proposed
ement statistics is presented in Supplementary data (Table S5).
Figure 9. (A) Postulated binding mode of benzimidazole inhibitors16 and (B) schematic representation consistent with the binding mode observed by X-ray crystallography
and including a water-mediated interaction of the benzimidazole scaffold with the hinge region.
Figure 8. (A) Overlay of the ligand 30-induced conformation (pink) and the CHK2 crystal structure of compound 19 (blue), compound 30 (green), compound 44 (purple) and
compound 47 (yellow). (B) Overlay of the ligand 30-induced conformation (pink) and the CHK2 crystal structure of compound 30 (green).
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mary carboxamide with respect to the benzimidazole scaffold;
however, a comparison of all four ligand-bound crystal structures
reveals a range of amide conformations (Fig. 8A), suggesting that
any rotational difference is within experimental error. We ob-
served no signiﬁcant differences between protein side chain con-
formations which deﬁne the active site across the four
experimentally derived crystal structures, supporting the selection
of a single protein conformation for compound docking. We used
the CHK2 protein conformation, including the conserved water
molecule, from the co-crystal structure of compound 30 to dock
the set of 50 ligands (Supplementary Table S1) using a rigid dock-
ing protocol. 40 Compounds from the 50 ligand set formed all 4
hydrogen bonds from the benzimidazole scaffold in their docked
poses consistent with the binding mode observed by X-ray
crystallography.
2.6. SAR is consistent with the observed binding mode
The observed binding mode for the benzimidazole series in
CHK2 is entirely consistent with the biochemical SAR data (Ta-
ble 1). All polar atoms of the amide and benzimidazole form hydro-
gen bonds, consistent with the experimental observation that
methylation of the benzimidazole N1 nitrogen atom (compound
8, Table 1) ablates activity (Fig. 9). Methylation at the N3 position
(compound 9, Table 1) would be predicted to reduce but not abol-
ish activity because, although the hydrogen bond interaction with
Glu308 would be lost, the water mediated interaction with thehinge via N1 is maintained. A possible steric clash between the
N3-methyl group and Glu308 is minimised by ﬂexibility of the glu-
tamic acid side chain. Replacement of the nitrogen at N3 by an oxy-
gen atom (compound 11, Table 1) would be predicted to lock the
tautomeric forms of the scaffold and compromise activity through
an unfavourable electrostatic clash with the carboxylic acid moiety
of Glu308.
The water-mediated interaction between the benzimidazole N1
atom and the hinge region is clearly observed in three of the four
protein ligand structures determined here, and there is evidence
for electron density corresponding to this water molecule in the
fourth structure; thus, this conserved water is an important deter-
minant of the observed benzimidazole binding mode. Inclusion of
this conserved water molecule in the NSC109555-derived protein
conformation was, therefore, inﬂuential in the discovery of the no-
vel benzimidazole binding mode by the in silico docking methods
described here. Recent reports highlight the beneﬁt of conserved
water molecule inclusion in docking protocols for kinases and
other gene families.46,47 The discovery of an optimal docking solu-
tion, consistent with the observed SAR, required inclusion of this
conserved water molecule and application of a docking protocol
incorporating the ﬂexibility of polar protein side chains.
3. Conclusions
The binding mode for a series of benzimidazole inhibitors of the
protein kinase CHK2 has been clariﬁed by application of ﬂexible
side chain docking and protein–ligand crystallography. Although
C. Matijssen et al. / Bioorg. Med. Chem. 20 (2012) 6630–6639 6637unconstrained rigid docking into the NSC109555-derived protein
structure produces favourable docking solutions, none is consis-
tent with the experimentally observed involvement of all four po-
lar atoms of the carboxamido–benzimidazole scaffold in binding.
However, the ﬂexible side chain docking produces an optimal pro-
tein conformation and ligand binding mode that is entirely consis-
tent with SAR from biochemical enzyme inhibition data. We
observed that polar and ﬂexible side chains: Lys249, Asp311, and
particularly Glu308, change conformation most signiﬁcantly in
the ligand-induced model whilst hydrophobic residues are largely
unchanged. The crystal structures of four exemplar benzimidazole
inhibitors bound to CHK2 all show a single binding mode which is
in excellent agreement with that obtained through ﬂexible dock-
ing, but different from the prediction of unconstrained rigid dock-
ing, and signiﬁcantly different from the binding modes previously
postulated in the literature. This experimentally conﬁrmed binding
mode to the hinge region of CHK2 through a conserved water mol-
ecule has previously been observed for NSC109555,43 but has not
previously been seen for a benzimidazole scaffold, and may pro-
vide a useful approach to selective small molecule inhibitor design
for CHK2.
4. Materials and methods
4.1. Compound selection
To assess the performance of side chain ﬂexible docking, active
compounds were selected from a published set of CHK2 inhibitors
with a benzimidazole scaffold, which were all characterised using
the same biochemical assay protocol.15–17 Compounds were de-
ﬁned as active if their biochemical IC50 was 100 nM or less. Ligands
with an ambiguous stereochemical assignment were removed
from the dataset leaving 50 compounds for analysis (compounds
1 and 13 to 61, Table S1, Supplementary data). To enable validation
of the ﬂexible docking results, a set of 5 compounds reported to be
inactive, or show signiﬁcantly reduced activity in the CHK2 bio-
chemical screen, was used as a negative control group (compounds
8 to 12, Table 1).
4.2. Ligand preparation
The benzimidazole core scaffold has two tautomeric forms both
of which were generated for docking studies. A preferred lowest-
energy 3D conformation was obtained for each compound using
Corina.48 The protonation state of compounds was assigned using
OpenEye Filter.49
4.3. Protein crystal structure preparation
CHK2 crystal structures (PDB ID: 2CN5 and 2W0J) representing
different ligand binding modes were obtained from the Protein
databank. To optimize the positioning of hydrogen atoms in the
ATP binding pocket, each crystal structure was subject to Proton-
ate3D as implemented in MOE50 using the default settings. Subse-
quently, the ligand and water molecules not interacting with the
hinge were removed.
4.4. Rigid docking
Unconstrained rigid docking was performed using GOLD.44 For
each compound, the number of binding poses generated was set
to 20. The search space was deﬁned by locating the centre of the
ligand present in each crystal structure (ADP for structure 2CN5
and NSC109555 for structure 2W0J) and using a radius of 16 Å
from the centroid to deﬁne the volume of the binding pocketsearched during docking. To ensure that all possible binding modes
were explored, early termination of the docking run as a conse-
quence of multiple solutions with the same binding mode was dis-
abled. Scoring of the binding poses was performed using
GOLDscore.45 The 20 top scoring poses were subject to further
analysis (see Section 4.6).
4.5. Flexible side chain docking
Unconstrained ﬂexible side chain docking was performed using
GOLD with the number of side chains treated as ﬂexible limited to
ten. For each protein crystal structure, an overlay was generated of
each pose from Rigid Docking which passed our PLIF ﬁlter (see Sec-
tion 4.6). The following residue selection criteria were then applied
in sequence:
1. Side chains with all heavy atoms outside a radius of 3.5 Å from
the nearest heavy atom of any ligand in its corresponding rigid
docking pose were deselected.31
2. Glycine and alanine residues were deselected because they do
not have a ﬂexible side chain.
3. Residues interacting with the ligand only via their backbone
atoms were deselected.
4. Residues with side chains pointing away from the ligand were
deselected.
Consistent with literature precedent that deﬁning objective criteria
for residue selection is difﬁcult31,32 further residues were deselect-
ed after manual inspection to prioritise 10 residues using the fol-
lowing criteria:
1. Residues with side chain ﬂexibility impaired by hydrogen bonds
and/or hydrophobic interactions with neighbouring residues
were deselected.
2. Residues were prioritised from those deeply buried in the bind-
ing pocket (highest priority) to those on the protein surface
(lowest priority) until the limit of 10 was achieved.
The permitted amount of ﬂexibility for the 10 selected residues
was deﬁned by the parameters Crystal and Library in GOLD as de-
scribed by Lovell et al.51 These settings allowed the side chains
to ﬂex around their initial positions with a maximal ﬂexibility in
line with the most commonly observed side chain conformations
of naturally occurring amino acids.48 The search space was deﬁned
as for rigid docking. For each compound, 20 protein-inhibitor com-
plexes were generated and scoring of the interaction between the
inhibitor and the induced protein conformation was performed
using GOLDscore.45 Early termination of the docking run, due to
the generation of multiple solutions with the same binding mode,
was disabled. The 20 top scoring poses were subject to further
analysis (see Section 4.6).
4.6. Analysis of docking results
To identify the protein residues interacting with a docked inhib-
itor, the resulting protein-inhibitor complexes were analysed using
the protein–ligand interaction ﬁngerprint (PLIF) implemented in
MOE, a method similar to the SIFt.52,53 The PLIF parameter ‘lower
interaction threshold’ was set to 2% to allow the detection of weak
hydrogen bonds between the ligand and the protein.54 The hinge-
binding interaction was used as a rigid anchor and maintained in
all compound-induced protein conformations. Compound poses
that did not form this key interaction were discarded. The number
of interactions for each compound pose with its induced protein
model was manually scored using the PLIF (Supplementary Tables
S3 and S4).
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Each ligand-induced protein conformation was analysed by
plotting the trade-off between the number of polar interactions
formed by the benzimidazole-5-carboxamide scaffold in the li-
gand-induced binding mode and the number of docked ligands
adopting that particular binding mode (Fig. 5 and Tables S3 and
S4). The selected ligand-induced protein conformation from this
trade-off surface had the optimal combination of a high number
of polar interactions and a high number of docked near neighbour
ligands adopting that particular binding mode. This selected li-
gand-induced protein conformation was conﬁrmed by application
of unconstrained rigid docking using GOLD as described above.
4.8. Protein production and crystallography
The CHK2 kinase domain (CHK2-KD, amino acids 210-531) was
produced as a GST-fusion protein and puriﬁed as previously de-
scribed.42 Co-crystallisation experiments with four selected benz-
imidazole inhibitors were carried out based upon conditions
described earlier.12,13,42 For full details of these experiments, crys-
tallographic data collection and reﬁnement see Supplementary
data and Table S6.
4.9. Chemistry methods
Compound structures have previously been disclosed although
preparative methods have not been described for all com-
pounds.15–17 Materials and methods used to prepare compounds
19, 30, 44 and 47 for protein–ligand crystallography are described
in Supplementary data.
4.10. Accession codes
Atomic coordinates and structure factors for the crystal struc-
tures of ligand-bound CHK2 can be accessed using the following
PDB codes: 19, 4A9S; 30, 4A9R; 44, 4A9T and 47, 4A9U.
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